teaser
Roche and Biogen Idec’s cancer drug Rituxan has been found to extend the lives of follicular lymphoma patients, according to a late-stage study.
The disease is a common, incurable but slow-developing form of non-Hodgkin’s lymphoma (NHL) and accounts for about one in four of all cases.
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
The study was stopped early after Rituxan, known as MabThera outside the US, met its target of extending the time patients live with their disease under control during a pre-planned interim analysis. Rituxan is co-marketed by Genentech.
Copyright Press Association 2009
